Auron Therapeutics
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
55 Chapel St Ste 100, Newton, Massachuse...Phone Number
(310) 922-5881Website
www.aurontx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Auron Therapeutics
Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a more normal phenotype.Explore more
Auron Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Auron Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Auron Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if Auron Therapeutics had a recent Job posting/layoffs
Check if Auron Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Auron Therapeutics recently announced quarterly report
Auron Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Auron Therapeutics has new funding data
Check out if Auron Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Auron Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Auron Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Auron Therapeutics
Compare insights from companies similar to Auron Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Auron Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Auron Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Auron Therapeutics.
Auron Therapeutics financials insights
Gather financial insights about Auron Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$12.8M
2022
Series A
$48M
2025
Series B
$27M
Auron Therapeutics Tech Stack
A closer look at the technologies used by Auron Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
Open Position
New Hire
Executive Move
Auron Therapeutics News & Media
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
Novel approach targeting KAT2A/B with preclinical validation across multiple cancer models and tumor types Novel approach targeting KAT2A/B with preclinical validation across multiple cancer models and tumor typesAuron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting
NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced preclinical data in prostate cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)
AUTX-703, a novel and potent oral KAT2A and KAT2B protein degrader, inhibits growth and induces profound, persistent cell state differentiation in SCLC models AUTX-703, a novel and potent oral KAT2A and KAT2B protein degrader, inhibits growth and induces profound, persistent cell state differentiation in SCLC modelsAuron Therapeutics Announces Poster Presentation at 2025 AACR Annual Meeting
NEWTON, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the Company will present updated preclinical data from its lead program, AUTX-703, during a poster session at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Auron Therapeutics
Sign Up For FreeTo access detailed company insights
Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a mor... Read More
